

## CLAIM AMENDMENTS

1. (Withdrawn.) A method for preventing photoaging in human skin, by administering an EGF-R protein tyrosine kinase inhibitor to the human whose skin is exposed to UV radiation.
2. (Withdrawn.) The method of claim 1, wherein the administration is topical.
3. (Withdrawn.) The method of claim 1, wherein the administration is prior to exposure to UV radiation.
4. (Withdrawn.) The method of claim 3, wherein the administration is at least six (6) hours prior to exposure.
5. (Withdrawn.) The method of claim 1, wherein the tyrosine kinase inhibitor is selected from the group consisting of isoflavones, suramin sodium (and related derivatives), heribimycin-A, lavendustin-A, erbstatin, benzylidenemalononitriles, brominated quinazolines, tyrphostins, phenylaminopyridines, pyrazolopyrimidines, pyrrolopyrimidines, thioindoles, dianilinophthalimides, anthraquinones, and mixtures thereof.
6. (Withdrawn.) The method of claim 4, further comprising administering a retinoid.
7. (Withdrawn.) The method of claim 5, wherein the isoflavone is genistein or quercetin.
8. (Currently amended.) A composition for ~~preventing~~ reducing the induction of MMPs in human skin due to exposure of the skin to UV radiation, comprising an effective amount of an EGF-R protein tyrosine kinase inhibitor admixed in a dermatologically suitable carrier therefor, wherein the EGF-R

inhibitor is selected from the group consisting of suramin sodium, heribimycin-A, tyrphostins, brominated quinazolines, phenylaminopyrimidines, pyrazolopyrimidines, pyrrolopyrimidines, thioindoles, dianilinophthalimides, anthraquinones, PD 153035, SU-5417, SU-6668, staurosporine, aeroplysinin, lavendustin A, piceatannol, hymenialdisine, and derivatives thereof, and mixtures thereof.

9. (Original.) The composition of claim 8, further comprising at least one additional compound selected from the group consisting of retinoids, P-450 inhibitors, antioxidants, UV sunscreens, and compatible mixtures thereof.

10. (Original.) The composition of claim 9, comprising a UVA blocker and a UVB blocker, and at least one additional compound selected from the group consisting of retinoids, P-450 inhibitors, and antioxidants, and compatible mixtures thereof.

11. (Original.) The composition of claim 10, wherein the additional compound is a retinoid.

12. (Original.) The composition of claim 11, wherein the retinoid is retinol.

13. (Currently amended.) A composition for ~~preventing~~ reducing the induction of MMPs in human skin due to exposure of the skin to UV radiation, comprising an effective amount of an EGF-R protein tyrosine kinase inhibitor and an effective amount of a retinoid admixed in a dermatologically suitable carrier therefor, wherein the EGF-R inhibitor is selected from the group consisting of suramin sodium, heribimycin-A, tyrphostins, brominated quinazolines, phenylaminopyrimidines, pyrazolopyrimidines, pyrrolopyrimidines, thioindoles,

dianilinophthalimides, anthraquinones, PD 153035, SU-5417, SU-6668, staurosporine, aeroplysinin, lavendustin A, piceatannol, hymenialdisine, and derivatives thereof, and mixtures thereof.

14. (Original.) The composition of claim 13, wherein the retinoid is retinol or retinoic acid.

15. (Currently amended.) The composition of claim 13, wherein the EGF-R inhibitor [[is]] further comprises an isoflavone.

16. (Original.) The composition of claim 15, wherein the isoflavone is genistein.

17. (New.) A composition for reducing the induction of MMPs in human skin due to exposure of the skin to UV radiation produced by the process comprising:

providing a non-isoflavone candidate compound;  
screening said candidate compound for ability to diminish activation of EGFR to identify a successful candidate compound; and  
admixing a non-toxic, effective amount of said successful candidate compound with a compatible dermatological carrier.

18. (New.) The composition of claim 17, further comprising admixing at least one additional compound selected from the group consisting of retinoids, P-450 inhibitors, antioxidants, UV sunscreens, and compatible mixtures thereof.

19. (New.) The composition of claim 18, wherein a retinoid, a P-450 inhibitor, and an antioxidant are admixed.

20. (New.) The composition of claim 18, wherein the antioxidant is selected from the group consisting of genistein, genistin, quercetin, glutathione,

N-acetyl cystein, green tea extract, carotenoids, tocopherols, ascorbic acid, lipoic acid, Erbstatin, and mixtures thereof.